Worldwide, nearly 150 million people are infected with hepatitis C, the leading cause of liver tran

The treatment of virus hepatitis C virus (HCV) is in full transformation: before final approval is expected in the antiviral and sofosbuvir simeprevir, ai se eu te pego and during the first half of 2014 of faldaprevir, and daclatasvir ABT-450 / r. At the last International Congress for the Study of the Liver (EASL) in Amsterdam, and has transpired, next to the presentation of papers on various drugs under investigation advanced, including the two that is 'have been published in The New England Journal of Medicine on sofosbuvir.
The two phase III studies of the drug have shown, first, that in patients infected with genotypes 2 or 3 virus of hepatitis C in the treatment with pegylated interferon and ribavirin was not possible, the administration of this sofosbuvir and between 12-16 weeks is effective. The authors of this study, coordinated by David R. Nelson at the University of Florida in Gainesville, highlight the efficacy ai se eu te pego was higher among patients infected with genotype 2 virus and those without cirrhosis, also in patients ai se eu te pego with genotype ai se eu te pego 3 treatment for sixteen weeks was more effective than twelve weeks.
In another study, the drug, which is prescribed as one pill daily, it selects a few resistors and associated side effects, got a 90 percent rate of sustained viral response administered next to pegylated interferon and ribavirin for twelve weeks in patients ai se eu te pego with predominantly genotype 1 or 4 virus.
The Congress has also addressed a review published in Expert Opinion Pharmacotherapy Group Vicente Soriano, ai se eu te pego the Infectious Diseases Hospital Carlos III (Madrid). It states that "among the HCV polymerase inhibitors, sofosbuvir has positioned itself as a partner of ribavirin in the treatment of most genotypes 2 or 3 of the hepatitis C virus, in combination with inhibitors of NS5A by other viral genotypes. "
Regarding ai se eu te pego the non-nucleoside polymerase inhibitors, "are being developed as part of combination therapy with orally administered protease inhibitors." The authors also note that the expected high price of these direct antiviral action (DDA in acronym) discarded extensive use of these drugs.
Worldwide, nearly 150 million people are infected with hepatitis C, the leading cause of liver transplantation and cancer. The solution to prevent transmission is the eradication of the virus, which is achieved in 60 percent of cases with interferon and ribavirin treatment.
The new direct antiviral action or AAD emerging as a promising new therapy for short (twelve weeks in some cases) and reduce side effects and complications, getting some up to 90 percent cure. Applying a mathematical model, scientists at Bristol University analyzed the latest issue of Hepatology at the possible impact of these drugs in the global ai se eu te pego control of hepatitis C.
Disclaimer
Asscat 2014 - All Rights Reserved.